p16-L16R patients without cancer (20% growth per day) showed a trend (p = 0.13 in two-tailed t-tests) toward higher growth rates than WT cells, supporting the idea that p16-L16R increases growth rates, even in subjects without cancer. Here, CDKN2A is linked to cancer.